[Platelet inhibition with prasugrel].

Abstract

Platelet activation plays a pivotal role in the pathogenesis of coronary artery disease. The long-term benefit of dual anti-platelet therapy with clopidogrel and aspirin is well established for patients with acute coronary syndrome and for secondary prophylaxis of coronary artery disease. This review discusses latest developments in the field of the thienopyridines. Particularly, we focus on the evidence-based use of prasugrel or prasugrel versus clopidogrel in clinical practice.

• Authors: N Gassanov, E Caglayan, A M Nia, E Erdmann, F Er
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 135 Issue 31-32 Pg. 1542-6 (Aug 2010) ISSN: 1439-4413 [Electronic] Germany
• Vernacular Title: Hemmung der Thrombozytenaggregation mit Prasugrel.
• PMID: 20665417 (Publication Type: Comparative Study, Journal Article, Review)
• Copyright: Georg Thieme Verlag KG Stuttgart, New York.

Chemical References

• Piperazines
• Platelet Aggregation Inhibitors
• Thiophenes
• Clopidogrel
• Prasugrel Hydrochloride
• Ticlopidine

Topics

• Acute Coronary Syndrome (blood, drug therapy)
• Administration, Oral
• Angina, Unstable (blood, drug therapy)
• Biological Availability
• Clopidogrel
• Coronary Artery Disease (blood, drug therapy)
• Humans
• Metabolic Clearance Rate (physiology)
• Piperazines (adverse effects, pharmacokinetics, therapeutic use)
• Platelet Aggregation Inhibitors (adverse effects, pharmacokinetics, therapeutic use)
• Prasugrel Hydrochloride
• Randomized Controlled Trials as Topic
• Secondary Prevention
• Thiophenes (adverse effects, pharmacokinetics, therapeutic use)
• Ticlopidine (analogs & derivatives, therapeutic use)